TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06697717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients
Description: The intervention, Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients, utilizes real-time transpulmonary pressure measurements (alveolar pressure minus pleural pressure, estimated via esophageal manometry) to individualize PEEP settings. This approach accounts for the impact of intra-abdominal hypertension (IAH) on pleural pressure and lung compliance, ensuring precise alveolar recruitment while minimizing overdistension and ventilation-induced lung injury (VILI). PEEP is titrated to maintain a positive end-expiratory transpulmonary pressure (e.g., \>0 cmH₂O) and optimal driving pressures, dynamically adjusted based on intra-abdominal pressure and lung mechanics. This method integrates advanced esophageal pressure monitoring with traditional parameters such as plateau pressure, compliance, and PaO₂/FiO₂ to guide clinical decisions. By addressing the pathophysiological interplay between thoracic and abdominal compartments, the intervention aims to enhance oxygen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT-Guided PEEP Titration in IAH and ARDS Patients
Description: The intervention, EIT-Guided PEEP Titration in IAH and ARDS Patients, utilizes electrical impedance tomography (EIT) to optimize PEEP settings based on real-time, regional lung ventilation and perfusion distribution. This approach differs from conventional methods that rely on global oxygenation or compliance indices by providing dynamic, bedside imaging of lung mechanics and aeration patterns. In patients with intra-abdominal hypertension (IAH) and ARDS, EIT identifies areas of alveolar overdistension and collapse, allowing precise PEEP titration to achieve optimal lung recruitment while minimizing ventilation-induced lung injury (VILI). The intervention dynamically adjusts PEEP levels to balance regional ventilation, enhance oxygenation, and mitigate the effects of IAH on thoracic mechanics. By integrating advanced imaging technology with traditional ventilatory parameters, this method offers a personalized strategy to improve respiratory mechanics and clinical outcomes.
Study: NCT04736706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD via oral tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule
Study: NCT05588193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVO
Description: post-visit outreach

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSH
Description: tele-sexual health visit during the ED visit
Study: NCT05917366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
Study: NCT05917366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coccyx Manipulation
Description: Application of manipulation to relax the levetor ani muscle
Study: NCT05608343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difamilast
Description: Off-white ointment containing active ingredient, petrolatum and other ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Difamilast (Study drug) ointment without active ingradient
Study: NCT05803720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV
Description: The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
Study: NCT04137133

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: collection
Description: bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
Study: NCT05339724

Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.

Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.

Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.

Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.

Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.

Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
Study: NCT05256056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: efficacy of bupivacaine in different volumes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: efficacy of bupivacaine in different volumes
Study: NCT05150756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
Description: At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulphate (10mg/ ml ampoule)
Description: At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
Study: NCT06102525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
Study: NCT05944458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N acetyl cysteine
Description: Fluimucil 600 mg iv to be taken twice daily as infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N acetyl cysteine
Description: Fluimucil 600 mg iv to be taken twice daily as infusion
Study: NCT01161394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05766020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listen training
Description: Auditory skills with the inclusion of cognitive control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listen training
Description: Auditory skills with the inclusion of cognitive control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listen training
Description: Auditory skills with the inclusion of cognitive control.
Study: NCT05329285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Alternative treatment
Study: NCT06102525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
Study: NCT05826509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: Radical prostatectomy with lymph node dissection will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative darolutamide + surgery.
Description: Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment.
Study: NCT04932707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sub-occipital muscle inhibition technique
Description: this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
Study: NCT06063655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control: Water
Description: Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control: Water
Description: Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
Study: NCT04932707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization
Description: Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control (passive stretch exercises)
Description: The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control (passive stretch exercises)
Description: The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
Study: NCT06063655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control: Water
Description: Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control: Water
Description: Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control: Water
Description: Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control: Water
Description: Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV hydration multiplier
Description: Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
Study: NCT04932707

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control (passive stretch exercises)
Description: The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
Study: NCT06063655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV hydration multiplier
Description: Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
Study: NCT05004272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: 20-minute manual full-body massage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gymnastics
Description: 20-minute moderate body workout

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lecture
Description: 20-minute lecture on medicinal herbs
Study: NCT05695833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Device emitting electric waves generating heat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Device emitting electric waves generating heat
Study: NCT06301035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asymmetric High flow nasal cannula
Description: * Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard(symmetric) High flow nasal cannula
Description: * Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary.
Study: NCT05029115

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Dapagliflozin, Empagliflozin
Study: NCT06162260

Intervention type: PROCEDURE
Intervention: ICU readmission
Description: Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
Study: NCT06063655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV hydration multiplier
Description: Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV hydration multiplier
Description: Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
Study: NCT06346457

Intervention type: DRUG
Intervention: Tamoxifen
Description: Tamoxifen is 20 mg once daily for two to three weeks.
Study: NCT06346457

Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.

Intervention type: DRUG
Intervention: Letrozole + GnRH
Description: When they take Letrozole + GnRh, the GnRh is an injection once a month.
Study: NCT06260644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VertiseTM flowable composite (Kerr,USA)
Description: self adhesive flowable resin composite restoration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VertiseTM flowable composite (Kerr,USA)
Description: self adhesive flowable resin composite restoration.
Study: NCT05856513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.
Study: NCT05909917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Half-Day First Responder Training
Description: Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half-Day First Responder Training
Description: Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
Study: NCT06292494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate 4000 Transcranial MRgfUS System
Description: Focused ultrasound interrupt structure of epilepsy network to improve seizure.